Utama › Leukemia Limfositik Kronik › Tennessee › Nashville
Kajian klinikal Leukemia Limfositik Kronik di Nashville, TN
13 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi dalam dan sekitar Nashville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Mengambil pesertaFasa 3
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mengambil pesertaFasa 3
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Mengambil pesertaFasa 3
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Mengambil pesertaFasa 2
- SCRI Oncology Partners, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Mengambil pesertaFasa 3
- SCRI Oncology Partners, Nashville
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Mengambil pesertaFasa 1/2
- SCRI Oncology Partners, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Mengambil pesertaFasa 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
- TriStar BMT, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Mengambil pesertaFasa 1
- Tennessee Oncology, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Mengambil pesertaFasa 4
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Mengambil pesertaFasa 4
- Tennessee Oncology, Nashville
HPC Offered for PRESERVE Expansion
Mengambil pesertaKajian pemerhatian
- Tristar Centennial Medical Center, Nashville
Kajian Leukemia Limfositik Kronik di bandar lain
- Boston, MA31 kajian
- Columbus, OH28 kajian
- Durham, NC27 kajian
- Washington, DC22 kajian
- Seattle, WA20 kajian
- Rochester, MN18 kajian
- New York City, NY18 kajian
- Houston, TX17 kajian
- Baldwin Park, CA16 kajian
- Milwaukee, WI15 kajian
- Chicago, IL14 kajian
- Cincinnati, OH14 kajian
Kajian lain di Nashville
- Kanser Paru-paru Bukan Sel Kecil97 kajian
- Kanser Payudara81 kajian
- Kanser Metastatik70 kajian
- Kanser Kolorektal69 kajian
- Kanser (semua jenis)65 kajian
- Kanser Ovari49 kajian
- Kanser Prostat43 kajian
- Kanser Paru-paru40 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher39 kajian
- Kanser Pankreas39 kajian
- Kanser Endometrium38 kajian
- Melanoma33 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.